REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

Kisspeptin-10

Metastin 45-54 / KP-10 / KISS1

Sexual Health

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides, derived from the KiSS-1 gene product. It is the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating GnRH neurons to initiate the reproductive hormone cascade. It is an emerging research compound in reproductive endocrinology, with applications in fertility diagnostics, IVF protocols, and understanding puberty initiation.

Mechanism of Action

C-terminal decapeptide fragment of kisspeptin that activates GPR54 (KISS1R) receptors on GnRH neurons. Potently stimulates the hypothalamic-pituitary-gonadal (HPG) axis, triggering pulsatile GnRH release and downstream LH and FSH secretion.

Research Protocols

For research purposes only. Not medical advice.

Research protocols use 1-10mcg/kg via IV infusion or subcutaneous injection. Single-dose studies commonly use 1nmol/kg IV. Very short-acting; effects on LH occur within minutes.

Research Notes

Clinical Research Status

Kisspeptin-10 is in early-phase clinical research primarily at academic centers, with Imperial College London leading human studies for IVF and reproductive disorders. Clinical trials have demonstrated its ability to trigger LH pulses and stimulate oocyte maturation as a potential alternative to HCG triggers in IVF. It is not yet approved for any therapeutic indication but has orphan-like research status in reproductive medicine.

Key Published Findings

Human studies demonstrate that kisspeptin-10 infusion (at doses of 0.1-1.0 nmol/kg) potently stimulates LH and FSH secretion in healthy volunteers and patients with reproductive disorders. In IVF contexts, kisspeptin-triggered oocyte maturation has produced viable pregnancies with theoretically lower risk of ovarian hyperstimulation syndrome compared to HCG triggers. Research confirms kisspeptin neurons are the critical gatekeepers of puberty onset, integrating metabolic and circadian signals to initiate HPG axis activation.

Safety Profile

Kisspeptin-10 has demonstrated an excellent safety profile in human clinical studies, with no serious adverse events reported across multiple Phase 1/2 trials. Its short half-life (approximately 4-5 minutes for kisspeptin-10) means effects are rapidly reversible, reducing risk of prolonged overstimulation. Unlike HCG triggers in IVF, kisspeptin stimulation produces a more physiological gonadotropin surge that may reduce ovarian hyperstimulation syndrome risk.

Comparison to Related Compounds

Unlike gonadorelin which directly activates GnRH receptors on the pituitary, kisspeptin acts one step further upstream by stimulating GnRH neurons themselves, producing a more physiological hormonal cascade. Compared to HCG for IVF triggering, kisspeptin produces a shorter and more physiological LH surge. The kisspeptin-54 (full-length) form has a longer half-life than kisspeptin-10 but both activate the same GPR54 (KISS1R) receptor.

Community Observations

Kisspeptin-10 has attracted interest from reproductive endocrinology researchers as a potentially safer alternative for IVF trigger protocols, particularly in OHSS-prone patients. The peptide's position at the apex of the HPG axis makes it a uniquely informative diagnostic tool for distinguishing hypothalamic from pituitary causes of hypogonadism. Its extremely short half-life currently limits practical therapeutic applications outside of controlled clinical settings.

Half-Life

~28 minutes

Reconstitution

Sterile saline or bacteriostatic water

Storage

Lyophilized

Store at -20C for long term.

Reconstituted

Refrigerate 2-8C. Use within 7 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Metastin 45-54KP-10KISS1

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer